Clinical outcomes of erlotinib, gefitinib, or pemetrexed in patients with non-squamous, non-small-cell lung cancer.
- Author:
La Young YOON
1
;
Mi Yean YANG
;
Jina YUN
;
Hyun Jung KIM
;
Han Jo KIM
;
Kyung Ha KIM
;
Se Hyung KIM
;
Sang Cheol LEE
;
Chan Kyu KIM
;
Nam Su LEE
;
Sung Kyu PARK
;
Kyu Taek LEE
;
Jong Ho WON
;
Hee Sook PARK
;
Dae Sik HONG
Author Information
1. Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine, Bucheon, Korea. dshong@schbc.ac.kr
- Publication Type:Original Article
- Keywords:
Carcinoma;
Non-small-cell lung cancer;
Erlotinib;
Gefitinib;
Pemetrexed
- MeSH:
Adenocarcinoma;
Disease-Free Survival;
Exanthema;
Female;
Follow-Up Studies;
Glutamates;
Guanine;
Humans;
Lung;
Lung Neoplasms;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Retrospective Studies;
Erlotinib Hydrochloride;
Pemetrexed
- From:Korean Journal of Medicine
2010;79(4):394-403
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: This study compared the clinical benefits of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) with pemetrexed to identify the clinical parameters that correlated with response. METHODS: A retrospective chart review examined patients who were 1) treated with EGFR TKI or pemetrexed, 2) diagnosed with advanced non-squamous non-small-cell lung cancer, and 3) previously treated with platinum-based chemotherapy in Soonchunhyang Bucheon Hospital. RESULTS: Sixty-one patients (18 erlotinib, 18 gefitinib, 25 pemetrexed) were investigated from February 2002 to August 2009. The median follow-up period was 37 months (7~97 months). Overall, their median age was 63 years, 41 patients were non-smokers, 57 patients had adenocarcinoma, and 55 patients were at stage IV. Twenty-one patients received the study drugs as second-line chemotherapy, and others as third-line or more. No significant differences in the overall response rate (erlotinib 33.3% vs. gefitinib 38.9% vs. pemetrexed 20.0%) and progression-free survival (erlotinib 1.9 months vs. gefitinib 3.0 months vs. pemetrexed 2.9 months) were found among the three groups. Female gender was related to a good response to EGFR TKIs (p=0.047). Skin rash in the erlotinib group (p=0.037) and adenocarcinoma in the pemetrexed group (p=0.02) were related to improved progression-free survival. Few side effects were reported. CONCLUSIONS: Both EGFR TKIs and pemetrexed therapy for non-squamous non-small-cell lung cancer were efficient and tolerable after the failure of first-line platinum-based chemotherapy. Further prospective studies are needed to validate the predictive role of the suggested clinical parameters in this study.
